Overview: 34-Beta E12 Immunohistochemistry TestIntroduction: The 34-Beta E12 Immunohistochemistry Test detects 34-Beta E12 (high molecular weight cytokeratin) to diagnose prostate cancer, causing urinary issues or pain. Aligned with 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected prostate cancer.
Other Names: 34-Beta E12 IHC Assay, Prostate Cancer IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: 34-Beta E12 testing began in the 1990s with prostate cancer research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects 34-Beta E12 to diagnose prostate cancer, guides treatment, and evaluates patients with urinary issues or pain.
Test Parameters: 1. 34-Beta E12 Protein
Pretest Condition: No fasting required. Collect tissue via prostate biopsy. Report history of urinary issues, pain, or elevated PSA.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document urinary issues, pelvic pain, elevated PSA, or family history of prostate cancer. Include current medications, especially hormone therapies.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect 34-Beta E12 in prostate tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for prostate cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Loss of 34-Beta E12 staining suggests prostate cancer, guiding surgery or radiation. Positive staining may indicate benign conditions, requiring further testing.
Specialist Consultation: Consult an oncologist or urologist for result interpretation and treatment planning.
Additional Supporting Tests: PSA, AMACR IHC, or prostate MRI to confirm prostate cancer.
Test Limitations: Not specific to prostate cancer; other conditions may affect staining. Clinical correlation is needed.
References: NCCN Prostate Cancer Guidelines, 2023; American Journal of Surgical Pathology, Epstein JI, 2022.
